TIVC icon

Tivic Health Systems

0.2146 USD
+0.0134
6.66%
At close Dec 20, 4:00 PM EST
After hours
0.2150
+0.0004
0.19%
1 day
6.66%
5 days
3.42%
1 month
-13.78%
3 months
-20.43%
6 months
-44.95%
Year to date
-88.14%
1 year
-87.07%
5 years
-99.96%
10 years
-99.96%
 

About: Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.

Employees: 9

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 10 [Q2] → 10 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

5.47% less ownership

Funds ownership: 10.01% [Q2] → 4.53% (-5.47%) [Q3]

73% less capital invested

Capital invested by funds: $241K [Q2] → $64.8K (-$176K) [Q3]

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Research analyst outlook

We haven’t received any recent analyst ratings for TIVC.

Financial journalist opinion

Neutral
Business Wire
1 month ago
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. “This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," st.
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update
Neutral
Seeking Alpha
1 month ago
Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript
Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Operator Welcome to Tivic Health Systems' Third Quarter 2024 Financial Results and Operational Update Conference Call. This call has been pre-recorded and questions you have submitted in advance will be answered following the prepared remarks.
Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript
Neutral
Business Wire
1 month ago
Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation (VNS) device. The study is being conducted by The Feinstein Institute of Bioelectronic Medicine. The objective of the study is to identify device parameters that optimally influence autonomi.
Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
Neutral
Business Wire
1 month ago
Tivic Health Validates European Patents in Great Britain, Germany, and France
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicinal devices, announced today that it has validated two granted European Patent Office (EPO) patents in Great Britain, Germany, and France. The Company believes these validations are an important step toward securing the foundation for an international market position. Newly validated patents in Great Britain, Germany and France: European Patent E.
Tivic Health Validates European Patents in Great Britain, Germany, and France
Neutral
Business Wire
1 month ago
Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be.
Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14
Neutral
Business Wire
1 month ago
First Subject Enrolled in Tivic Health's Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject has been enrolled in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation device. The study, being run by The Feinstein Institute of Bioelectronic Medicine, will identify device parameters, including frequency and duration of treatment, that optimally influ.
First Subject Enrolled in Tivic Health's Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
Neutral
Business Wire
1 month ago
Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024
SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst's presentation, Tuesday, October 29 at 2:30 p.m. EDT, will focus on the company's advances in bioelectronic medicine, including its recently released data on a new approach to vagus nerve stimulation. “This yea.
Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024
Neutral
Business Wire
3 months ago
Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment
SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it has received approval from The Feinstein Institutes' Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation (“ncVNS”) approach. This clinical research collaboration with Feinstein is designed to advance the development of Tivic Health's ncVNS.
Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment
Neutral
Business Wire
3 months ago
Tivic Health Accelerates VNS Commercial Strategy Development
SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght (“FSI”), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation (“ncVNS”). Polaris Market Research estimates the global vagus nerve stimulation market will grow from $8.59 billion in.
Tivic Health Accelerates VNS Commercial Strategy Development
Neutral
Business Wire
3 months ago
Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer
SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions.
Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer
Charts implemented using Lightweight Charts™